# The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel

> **NCT03599284** · PHASE2 · COMPLETED · sponsor: **Jiangsu vcare pharmaceutical technology co., LTD** · enrollment: 279 (actual)

## Conditions studied

- Coronary Artery Disease
- Percutaneous Coronary Intervention
- Platelet Aggregation Inhibitors

## Interventions

- **DRUG:** Vicagrel 5mg
- **DRUG:** Vicagrel 6mg
- **DRUG:** Vicagrel 7.5mg
- **DRUG:** Clopidogrel 75mg

## Key facts

- **NCT ID:** NCT03599284
- **Lead sponsor:** Jiangsu vcare pharmaceutical technology co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-30
- **Primary completion:** 2019-06-11
- **Final completion:** 2019-07-28
- **Target enrollment:** 279 (ACTUAL)
- **Last updated:** 2019-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03599284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03599284, "The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03599284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*